# Veeco Instruments Inc: financial statements, quarterly

VECO · Nasdaq · CIK 103145 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/veco.md) · [Financials](/companies/veco/financials.md) · [Filings](/companies/veco/filings.md) · [Insiders](/companies/veco/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/veco/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [177](/filings/0001558370-24-014651.md) | [174 d](/filings/0001104659-26-019711.md) | [174](/filings/0001558370-25-006755.md) | [176](/filings/0001558370-25-010544.md) | [185](/filings/0001104659-25-107052.md) | [182 d](/filings/0001104659-26-019711.md) | [167](/filings/0001104659-26-055672.md) | [166](/filings/0001104659-26-091158.md) | [166](/filings/0001104659-25-107052.md) | [165 d](/filings/0001104659-26-019711.md) | [158](/filings/0001104659-26-055672.md) | [193](/filings/0001104659-26-091158.md) |
| Cost of revenue | $m | [100](/filings/0001558370-24-014651.md) | [95.3 d](/filings/0001104659-26-019711.md) | [99.1](/filings/0001558370-25-006755.md) | [100](/filings/0001558370-25-010544.md) | [106](/filings/0001104659-25-107052.md) | [108 d](/filings/0001104659-26-019711.md) | [98.8](/filings/0001104659-26-055672.md) | [97.4](/filings/0001104659-26-091158.md) | [98.2](/filings/0001104659-25-107052.md) | [105 d](/filings/0001104659-26-019711.md) | [103](/filings/0001104659-26-055672.md) | [119](/filings/0001104659-26-091158.md) |
| Gross profit | $m | [76.9](/filings/0001558370-24-014651.md) | [78.7 d](/filings/0001104659-26-019711.md) | [75.4](/filings/0001558370-25-006755.md) | [75.4](/filings/0001558370-25-010544.md) | [79.2](/filings/0001104659-25-107052.md) | [74.0 d](/filings/0001104659-26-019711.md) | [68.5](/filings/0001104659-26-055672.md) | [68.7](/filings/0001104659-26-091158.md) | [67.7](/filings/0001104659-25-107052.md) | [60.5 d](/filings/0001104659-26-019711.md) | [55.8](/filings/0001104659-26-055672.md) | [74.8](/filings/0001104659-26-091158.md) |
| Research and development | $m | [28.8](/filings/0001558370-24-014651.md) | [29.1 d](/filings/0001104659-26-019711.md) | [29.6](/filings/0001558370-25-006755.md) | [31.7](/filings/0001558370-25-010544.md) | [32.2](/filings/0001104659-25-107052.md) | [31.0 d](/filings/0001104659-26-019711.md) | [28.5](/filings/0001104659-26-055672.md) | [31.6](/filings/0001104659-26-091158.md) | [29.0](/filings/0001104659-25-107052.md) | [30.6 d](/filings/0001104659-26-019711.md) | [29.9](/filings/0001104659-26-055672.md) | [33.3](/filings/0001104659-26-091158.md) |
| Selling, general and administrative | $m | [22.8](/filings/0001558370-24-014651.md) | [23.5 d](/filings/0001104659-26-019711.md) | [24.7](/filings/0001558370-25-006755.md) | [24.6](/filings/0001558370-25-010544.md) | [25.3](/filings/0001104659-25-107052.md) | [25.1 d](/filings/0001104659-26-019711.md) | [25.0](/filings/0001104659-26-055672.md) | [23.9](/filings/0001104659-26-091158.md) | [27.3](/filings/0001104659-25-107052.md) | [22.7 d](/filings/0001104659-26-019711.md) | [26.0](/filings/0001104659-26-055672.md) | [27.6](/filings/0001104659-26-091158.md) |
| Operating income | $m | [22.3](/filings/0001558370-24-014651.md) | [24.2 d](/filings/0001104659-26-019711.md) | [22.0](/filings/0001558370-25-006755.md) | [16.7](/filings/0001558370-25-010544.md) | [24.3](/filings/0001104659-25-107052.md) | [3.9 d](/filings/0001104659-26-019711.md) | [14.1](/filings/0001104659-26-055672.md) | [12.4](/filings/0001104659-26-091158.md) | [10.6](/filings/0001104659-25-107052.md) | [(1.4) d](/filings/0001104659-26-019711.md) | [(2.7)](/filings/0001104659-26-055672.md) | [11.9](/filings/0001104659-26-091158.md) |
| Interest expense | $m | [2.8](/filings/0001558370-23-017774.md) | [3.1 d](/filings/0001558370-24-001289.md) | [2.6](/filings/0001558370-24-007070.md) | [2.8](/filings/0001558370-25-010544.md) | [2.9](/filings/0001104659-25-107052.md) | [2.8 d](/filings/0001104659-26-019711.md) | [2.5](/filings/0001104659-26-055672.md) | [2.3](/filings/0001104659-26-091158.md) | [2.2](/filings/0001104659-25-107052.md) | [2.2 d](/filings/0001104659-26-019711.md) | [2.1](/filings/0001104659-26-055672.md) | [2.2](/filings/0001104659-26-091158.md) |
| Income tax | $m | [(2.1)](/filings/0001558370-24-014651.md) | [2.5 d](/filings/0001104659-26-019711.md) | [0.9](/filings/0001558370-25-006755.md) | [2.1](/filings/0001558370-25-010544.md) | [2.7](/filings/0001104659-25-107052.md) | [(10.6) d](/filings/0001104659-26-019711.md) | [3.0](/filings/0001104659-26-055672.md) | [0.9](/filings/0001104659-26-091158.md) | [1.3](/filings/0001104659-25-107052.md) | [(1.2) d](/filings/0001104659-26-019711.md) | [(1.2)](/filings/0001104659-26-055672.md) | [1.2](/filings/0001104659-26-091158.md) |
| Net income | $m | [24.6](/filings/0001558370-24-014651.md) | [21.6 d](/filings/0001104659-26-019711.md) | [21.9](/filings/0001104659-25-107052.md) | [14.9](/filings/0001104659-25-107052.md) | [22.0](/filings/0001104659-25-107052.md) | [15.0 d](/filings/0001104659-26-019711.md) | [11.9](/filings/0001104659-26-091158.md) | [11.7](/filings/0001104659-26-091158.md) | [10.6](/filings/0001104659-25-107052.md) | [1.1 d](/filings/0001104659-26-019711.md) | [(0.3)](/filings/0001104659-26-091158.md) | [11.9](/filings/0001104659-26-091158.md) |
| Diluted EPS | $ per share | [0.42](/filings/0001558370-24-014651.md) | not reported | [0.37](/filings/0001558370-25-006755.md) | [0.25](/filings/0001558370-25-010544.md) | [0.36](/filings/0001104659-25-107052.md) | not reported | [0.20](/filings/0001104659-26-055672.md) | [0.20](/filings/0001104659-26-091158.md) | [0.17](/filings/0001104659-25-107052.md) | not reported | [(0.01)](/filings/0001104659-26-055672.md) | [0.18](/filings/0001104659-26-091158.md) |
| Basic EPS | $ per share | [0.44](/filings/0001558370-24-014651.md) | not reported | [0.39](/filings/0001558370-25-006755.md) | [0.27](/filings/0001558370-25-010544.md) | [0.39](/filings/0001104659-25-107052.md) | not reported | [0.21](/filings/0001104659-26-055672.md) | [0.20](/filings/0001104659-26-091158.md) | [0.18](/filings/0001104659-25-107052.md) | not reported | [(0.01)](/filings/0001104659-26-055672.md) | [0.19](/filings/0001104659-26-091158.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [156](/filings/0001558370-23-017774.md) | [159](/filings/0001558370-25-001001.md) | [174](/filings/0001558370-24-007070.md) | [174](/filings/0001558370-24-011106.md) | [163](/filings/0001558370-24-014651.md) | [146](/filings/0001104659-26-019711.md) | [175](/filings/0001558370-25-006755.md) | [189](/filings/0001558370-25-010544.md) | [193](/filings/0001104659-25-107052.md) | [163](/filings/0001104659-26-091158.md) | [180](/filings/0001104659-26-055672.md) | [214](/filings/0001104659-26-091158.md) |
| Current assets | $m | [721](/filings/0001558370-23-017774.md) | [706](/filings/0001558370-25-001001.md) | [716](/filings/0001558370-24-007070.md) | [718](/filings/0001558370-24-011106.md) | [761](/filings/0001558370-24-014651.md) | [765](/filings/0001104659-26-019711.md) | [795](/filings/0001558370-25-006755.md) | [792](/filings/0001558370-25-010544.md) | [810](/filings/0001104659-25-107052.md) | [845](/filings/0001104659-26-091158.md) | [873](/filings/0001104659-26-055672.md) | [930](/filings/0001104659-26-091158.md) |
| Total assets | $m | [1,246](/filings/0001558370-23-017774.md) | [1,229](/filings/0001558370-25-001001.md) | [1,234](/filings/0001558370-24-007070.md) | [1,235](/filings/0001558370-24-011106.md) | [1,273](/filings/0001558370-24-014651.md) | [1,252](/filings/0001104659-26-019711.md) | [1,279](/filings/0001558370-25-006755.md) | [1,275](/filings/0001558370-25-010544.md) | [1,290](/filings/0001104659-25-107052.md) | [1,326](/filings/0001104659-26-091158.md) | [1,353](/filings/0001104659-26-055672.md) | [1,414](/filings/0001104659-26-091158.md) |
| Current liabilities | $m | [268](/filings/0001558370-23-017774.md) | [218](/filings/0001558370-25-001001.md) | [234](/filings/0001558370-24-007070.md) | [204](/filings/0001558370-24-011106.md) | [215](/filings/0001558370-24-014651.md) | [192](/filings/0001104659-26-019711.md) | [179](/filings/0001558370-25-006755.md) | [155](/filings/0001558370-25-010544.md) | [151](/filings/0001104659-25-107052.md) | [178](/filings/0001104659-26-091158.md) | [207](/filings/0001104659-26-055672.md) | [237](/filings/0001104659-26-091158.md) |
| Total liabilities | $m | [602](/filings/0001558370-23-017774.md) | [557](/filings/0001558370-25-001001.md) | [546](/filings/0001558370-24-007070.md) | [520](/filings/0001558370-24-011106.md) | [526](/filings/0001558370-24-014651.md) | [481](/filings/0001104659-26-019711.md) | [467](/filings/0001558370-25-006755.md) | [419](/filings/0001558370-25-010544.md) | [414](/filings/0001104659-25-107052.md) | [440](/filings/0001104659-26-091158.md) | [469](/filings/0001104659-26-055672.md) | [512](/filings/0001104659-26-091158.md) |
| Long-term debt | $m | [275](/filings/0001558370-23-017774.md) | [275](/filings/0001558370-25-001001.md) | [249](/filings/0001558370-24-007070.md) | [249](/filings/0001558370-24-011106.md) | [249](/filings/0001558370-24-014651.md) | [250](/filings/0001104659-26-019711.md) | [250](/filings/0001558370-25-006755.md) | [225](/filings/0001558370-25-010544.md) | [226](/filings/0001104659-25-107052.md) | [226](/filings/0001104659-26-091158.md) | [226](/filings/0001104659-26-055672.md) | [227](/filings/0001104659-26-091158.md) |
| Current portion of debt | $m | not reported | not reported | [26.4](/filings/0001558370-24-007070.md) | [26.4](/filings/0001558370-24-011106.md) | [26.5](/filings/0001558370-24-014651.md) | [26.5](/filings/0001104659-26-019711.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [644](/filings/0001558370-24-014651.md) | [672](/filings/0001104659-26-019711.md) | [688](/filings/0001104659-25-107052.md) | [715](/filings/0001104659-25-107052.md) | [747](/filings/0001104659-25-107052.md) | [771](/filings/0001104659-26-091158.md) | [812](/filings/0001104659-26-091158.md) | [856](/filings/0001104659-26-091158.md) | [876](/filings/0001104659-25-107052.md) | [886](/filings/0001104659-26-091158.md) | [884](/filings/0001104659-26-091158.md) | [903](/filings/0001104659-26-091158.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [7.1 d](/filings/0001558370-24-014651.md) | [29.5 d](/filings/0001104659-26-019711.md) | [9.4](/filings/0001558370-25-006755.md) | [8.5 d](/filings/0001558370-25-010544.md) | [17.6 d](/filings/0001104659-25-107052.md) | [28.4 d](/filings/0001104659-26-019711.md) | [20.0](/filings/0001104659-26-055672.md) | [9.0 d](/filings/0001104659-26-091158.md) | [15.5 d](/filings/0001104659-25-107052.md) | [24.9 d](/filings/0001104659-26-019711.md) | [7.9](/filings/0001104659-26-055672.md) | [51.4 d](/filings/0001104659-26-091158.md) |
| Capital expenditure | $m | [6.4 d](/filings/0001558370-24-014651.md) | [10.7 d](/filings/0001104659-26-019711.md) | [6.0](/filings/0001558370-25-006755.md) | [3.0 d](/filings/0001558370-25-010544.md) | [4.0 d](/filings/0001104659-25-107052.md) | [5.2 d](/filings/0001104659-26-019711.md) | [6.8](/filings/0001104659-26-055672.md) | [3.6 d](/filings/0001104659-26-091158.md) | [2.6 d](/filings/0001104659-25-107052.md) | [3.3 d](/filings/0001104659-26-019711.md) | [5.1](/filings/0001104659-26-055672.md) | [3.7 d](/filings/0001104659-26-091158.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [65.2](/filings/0001558370-23-017774.md) | [59.9](/filings/0001558370-24-007070.md) | [52.9](/filings/0001558370-24-011106.md) | [59.6](/filings/0001558370-24-014651.md) | [60.8](/filings/0001558370-25-006755.md) | [62.5](/filings/0001558370-25-010544.md) | [62.7](/filings/0001104659-25-107052.md) | [60.2](/filings/0001104659-26-055672.md) | [60.2](/filings/0001104659-26-091158.md) | [61.0](/filings/0001104659-25-107052.md) | [60.4](/filings/0001104659-26-055672.md) | [66.8](/filings/0001104659-26-091158.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,129,640 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001104659-26-091158.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.